A Phase 2/3, open-label, randomized study of telisotuzumab adizutecan compared with standard of care in patients with locally advanced or metastatic non-squamous non-small cell lung cancer with an EGFR mutation, following progression on a third-generation TKI.
Principal Investigator
Dott.ssa Vanesa Gregorc
Contact Information for Access
Phase
FASE II
Status
ATTIVO
Objective of the study
The primary objective is to evaluate the efficacy of telisotuzumab adizutecan compared with the standard of care in patients with EGFR-mutated non-squamous NSCLC following progression on a third-generation TKI.
Lung - EGFR-mutated NSCLC
Sponsor: AbbVie
Pathologies
Lung Cancer
Medication
Osimertinib
, Telisotuzumab Adizutecan
Who is eligible to participate in the study?
Patients who are 18 years of age or older and meet the study’s eligibility criteria—and who have previously been treated for EGFR-mutated NSCLC—may participate in this study.
Back to search page